Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in Psychotropic Drug Concentrations Across the Menstrual Cycle: A Pilot Study.
Spadi J, Scherf-Clavel M, Leutritz AL, Hütz B, Matentzoglu M, Nieberler M, Kurlbaum M, Hahner S, Bartmann C, McNeill RV, Kittel-Schneider S. Spadi J, et al. Among authors: kurlbaum m. Ther Drug Monit. 2024 Apr 1;46(2):195-202. doi: 10.1097/FTD.0000000000001182. Epub 2024 Jan 30. Ther Drug Monit. 2024. PMID: 38321601
Endocrine Disruptors: Focus on the Adrenal Cortex.
Pötzl B, Kürzinger L, Stopper H, Fassnacht M, Kurlbaum M, Dischinger U. Pötzl B, et al. Among authors: kurlbaum m. Horm Metab Res. 2024 Jan;56(1):78-90. doi: 10.1055/a-2198-9307. Epub 2023 Oct 26. Horm Metab Res. 2024. PMID: 37884032 Free PMC article. Review.
FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C, Tamburello M, Rossini E, Zini S, Durand N, Cantini G, Cioppi F, Hantel C, Kiseljak-Vassiliades K, Wierman ME, Landwehr LS, Weigand I, Kurlbaum M, Zizioli D, Turtoi A, Yang S, Berruti A, Luconi M, Sigala S, Lalli E. Ruggiero C, et al. Among authors: kurlbaum m. Int J Cancer. 2023 Jul 1;153(1):210-223. doi: 10.1002/ijc.34526. Epub 2023 Mar 31. Int J Cancer. 2023. PMID: 36971100
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, Kalogirou C, Goebeler ME, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Zimmermann S, et al. Among authors: kurlbaum m. J Pharm Biomed Anal. 2023 May 10;228:115311. doi: 10.1016/j.jpba.2023.115311. Epub 2023 Feb 23. J Pharm Biomed Anal. 2023. PMID: 36841066
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Gerner B, et al. Among authors: kurlbaum m. Pharmaceutics. 2022 Nov 22;14(12):2556. doi: 10.3390/pharmaceutics14122556. Pharmaceutics. 2022. PMID: 36559050 Free PMC article.
42 results